Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.

Autor:	Cheng R; Division of Cardiology, University of Washington, Seattle, Washington, USA., Kittleson MM; Cardiology, Cedars Sinai Heart Institute, Los Angeles, California, USA., Wechalekar AD; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK., Alvarez-Cardona J; Cardiology, New York University Grossman School of Medicine, New York, New York, USA., Mitchell JD; Cardiology/IM, Washington University in St Louis, St Louis, Missouri, USA., Scarlatelli Macedo AV; Cardiology, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil., Dutra JPP; Center for Oncological Research (CEPON) and SOS Cardio Hospital in Florianópolis, Santa Catarina, Brazil., Campbell CM; Baylor Scott and White Heart and Vascular Hospital, Baylor University Medical Center, Dallas, Texas, USA., Liu JE; Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Landau HJ; Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Davis MK; Cardiology, University of British Columbia, Vancouver, British Columbia, Canada., Morrissey S; Oncology, Barnes Hospital School of Nursing, Saint Louis, Missouri, USA., Casselli S; International Cardio-Oncology Society, Tampa, Florida, USA., Lousada I; Amyloidosis Research Consortium, Newton, Massachusetts, USA., Seabra-Garcez JD; Hospital Primavera, Aracaju, Sergipe, Brazil., Szor RS; Hospital 9 de Julho, São Paulo, Brazil., Ganatra S; Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Trachtenberg B; Houston Methodist Hospital, Houston, Texas, USA., Maurer MS; Center for Advanced Cardiac Care, Columbia University Medical Center, New York, New York, USA., Stockerl-Goldstein K; Oncology, Washington University in St Louis, St Louis, Missouri, USA., Lenihan D; Cardiology, International Cardio-Oncology Society and St Frances Healthcare, Cape Girardeau, Missouri, USA cardio-oncologydoc@protonmail.com.
Jazyk:	angličtina
Zdroj:	Heart (British Cardiac Society) [Heart] 2024 May 23; Vol. 110 (12), pp. 823-830. Date of Electronic Publication: 2024 May 23.
DOI:	10.1136/heartjnl-2023-323502
Abstrakt:	The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due to the complexity of amyloidosis, centralised expert providers with experience in delineating the nuances of confirmatory diagnosis and management may be beneficial. There are many potential benefits of a centre of excellence designation for the treatment of amyloidosis including recognition of institutions that have been leading the way for the optimal treatment of this condition, establishing the expectations for any centre who is engaging in the treatment of amyloidosis and developing cooperative groups to allow more effective research in this disease space. Standardising the expectations and criteria for these centres is essential for ensuring the highest quality of clinical care and community education. In order to define what components are necessary for an effective centre of excellence for the treatment of amyloidosis, we prepared a survey in cooperation with a multidisciplinary panel of amyloidosis experts representing an international consortium. The purpose of this position statement is to identify the essential elements necessary for highly effective clinical care and to develop a general standard with which practices or institutions could be recognised as a centre of excellence. Competing Interests: Competing interests: JM is a consultant (modest) for Bridgebio. SM has received speaker fees from AstraZeneca, Pfizer, Janssen, Astellas, Bayer and Edwards, and is on advisory boards for Pfizer and AstraZeneca. SC is employed by International Cardio-Oncology Society (IC-OS), a non-profit company. IL is the founder of the Amyloidosis Research Consortium. DL is a member of a data safety board for Intellia and a consultant for the IC-OS. All other authors report no conflicts. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu